

The dangers of parental consent start before obstetric care



TO THE EDITORS: The “Call to Action” issued by Dr Bortoletto and colleagues focuses attention on a key population.¹ As with many transitions, that between adolescence and adulthood exposes adolescents to the risk of being subject to the rules of both and the privileges of neither. It is essential to ensure that adolescents are empowered to receive the quality prenatal and obstetric options and care that all women deserve. However, it is critical to note that our failure to ensure that adolescents receive comprehensive reproductive health care predates their first prenatal visit. Currently, 21 states have laws requiring parental consent, 11 have laws mandating prior parental notification, and 5 have both. Six states have laws that have been temporarily or permanently enjoined.² Given that 75% of pregnancies among adolescents are unintended, the right to choose how to manage a pregnancy must be part of a conversation about adolescent reproductive care.³

Dr Espey and colleagues elegantly outline the importance of full reproductive autonomy for all women, and particularly for adolescents, in their articles in this journal, with the support of our subspecialty societies and the Society for Adolescent Health and Medicine.⁴ In this spirit, I echo Dr Bortoletto's call and urge us to consider not just obstetric care or gynecologic care, but women's care. ■

Anuja Singh, MD
Division of Family Planning
Department of Obstetrics and Gynecology
University of North Carolina, Chapel Hill
Chapel Hill, NC
anuja_singh@med.unc.edu

The author reports no conflict of interest.

Fellowship supported by grant from the Society of Family Planning.

REFERENCES

1. Bortoletto P, Dethier D, Evans T, Tracy E. Parental consent: an unnecessary barrier to adolescent obstetric care. *Am J Obstet Gynecol* 2018;219:451.
2. Guttmacher Institute. Fact sheet. Available at: <https://www.guttmacher.org/state-policy/explore/overview-minors-consent-law>. Accessed November 6, 2018.
3. Finer L, Zolnra MR. Declines in unintended pregnancy in the United States, 2008-2011. *N Engl J Med* 2016;374:843-52.
4. Espey E, Dennis A, Landy U. The importance of access to comprehensive reproductive health care, including abortion: a statement from women's health professional organizations. *Am J Obstet Gynecol* 2019;220:67-70.

Published by Elsevier Inc. <https://doi.org/10.1016/j.ajog.2018.12.017>

Are early screening biomarkers for endometrial cancer needed to reduce health disparities?



TO THE EDITORS: We read with interest the study by Doll et al,¹ highlighting the health disparities that the reliance on patient recognition of the most common endometrial cancer early sign (postmenopausal bleeding) and appropriate clinical follow-up has created. As the authors show, while it is remarkable that more than 90% of women diagnosed with endometrial cancer report vaginal bleeding, this number conceals the third largest racial disparity in US cancers among women. Although endometrial cancer is diagnosed more often in white than black women (27 vs 25 per 100,000), it kills double the number of black women (8 vs 4 per 100,000).² The authors indicate a variety of contributing factors to this disparity and suggest that future work should focus on changing provider perceptions and patient expectations, which is undoubtedly needed.

Screening tests are not used or needed for the majority of patients with endometrial cancer. However, to address the disparities affecting subgroups of patients with delayed diagnosis, identification of early biomarkers may potentially help. This is because the current approach for the detection of endometrial cancer relies entirely on the premise that all patients are able to recognize early symptoms, able to report it, and that the clinicians will be adequately responsive.

This framework has worked very well for white patients, resulting in a 15% mortality rate (4 deaths per 27 individual diagnostic rate) but terribly for black patients, who have a mortality rate of 32% (8 deaths per 25 individual diagnostic rate). Relying solely on symptom-driven manifestation, reporting, and follow-up has created multiple levels of disparities. An early screening biomarker will not fix all problems, but it will standardize the approach into a more objective one. In breast cancer, whose diagnosis is primarily screen based, the white and black mortality rate is much more balanced (16% for white vs 23% for black patients).

In endometrial cancer we have the luxury of being able to detect it early in its progression in most women. Let us not let that luxury be the nail in the coffin for those who do not have it. There are developing screening and prevention options, which include epigenetic³ and microbiome⁴ biomarkers. These early detection biomarkers may one day allow the identification of patients in the path to carcinogenesis and lead to primary prevention interventions that may end the status of endometrial cancer as the most common gynecologic cancer among all women. ■